Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) Short Interest Update

Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) was the recipient of a significant decline in short interest in the month of February. As of February 13th, there was short interest totaling 1,533 shares, a decline of 53.3% from the January 29th total of 3,281 shares. Based on an average trading volume of 5,511 shares, the short-interest ratio is currently 0.3 days. Currently, 0.0% of the company’s shares are sold short. Currently, 0.0% of the company’s shares are sold short. Based on an average trading volume of 5,511 shares, the short-interest ratio is currently 0.3 days.

Invesco Biotechnology & Genome ETF Trading Up 0.8%

Shares of NYSEARCA PBE traded up $0.63 during mid-day trading on Friday, reaching $81.97. 269 shares of the company’s stock were exchanged, compared to its average volume of 6,576. Invesco Biotechnology & Genome ETF has a twelve month low of $54.52 and a twelve month high of $85.73. The firm has a market capitalization of $263.12 million, a price-to-earnings ratio of 20.44 and a beta of 0.79. The business has a fifty day simple moving average of $82.59 and a 200 day simple moving average of $76.76.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in PBE. Gerber Kawasaki Wealth & Investment Management raised its stake in shares of Invesco Biotechnology & Genome ETF by 4.2% in the 2nd quarter. Gerber Kawasaki Wealth & Investment Management now owns 254,172 shares of the company’s stock valued at $16,292,000 after purchasing an additional 10,213 shares during the period. Allworth Financial LP acquired a new stake in Invesco Biotechnology & Genome ETF in the 2nd quarter valued at approximately $54,000. Colonial Trust Advisors bought a new stake in Invesco Biotechnology & Genome ETF in the 4th quarter valued at approximately $25,000. LPL Financial LLC boosted its position in Invesco Biotechnology & Genome ETF by 5.0% during the 4th quarter. LPL Financial LLC now owns 97,304 shares of the company’s stock worth $7,994,000 after acquiring an additional 4,617 shares during the last quarter. Finally, Advisory Services Network LLC bought a new position in shares of Invesco Biotechnology & Genome ETF during the 3rd quarter worth approximately $82,000.

About Invesco Biotechnology & Genome ETF

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.